-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Exagen, Lowers Price Target to $8

Benzinga·05/12/2026 10:49:44
Listen to the news
BTIG analyst Mark Massaro maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $9 to $8.